Fact-check: Speed Pharmacology's incretin segment in Drugs for Diabetes

What the video covers

This is a whole-class lecture: insulins, amylin analogues, incretin mimetics, DPP-4 inhibitors, sulfonylureas, glinides, metformin, thiazolidinediones, SGLT2 inhibitors and the rest. We include it for the three minutes on incretins, which remain one of the clearest short explanations on YouTube of why GLP-1 drugs exist at all.

What it gets right

The core logic is correct and well sequenced. Incretins are gut hormones released in response to food that amplify insulin secretion; the two that matter are GLP-1 and GIP; native GLP-1 is inactivated within minutes by the enzyme DPP-4; and the solution was to build GLP-1 mimetics that resist DPP-4, with exenatide and liraglutide as the examples available in 2017. The lecture then lists the effects beyond insulin: slowed gastric emptying, increased satiety and, as a consequence, weight loss, with nausea, vomiting, diarrhoea and constipation as the common adverse effects. Every one of those statements appears in the clinical pharmacology and adverse reactions sections of the current semaglutide label.

The DPP-4 inhibitor contrast is also useful. Blocking the enzyme raises native incretin levels modestly, which is why gliptins lower glucose without the appetite and weight effects of a receptor agonist given at pharmacological doses. That distinction explains why nobody loses 15 percent of their weight on sitagliptin.

What it leaves out or overstates

The video is nine years old and it shows in three places. First, the drugs. Semaglutide (Ozempic, approved December 2017), tirzepatide (Mounjaro, May 2022) and their weight-management versions do not appear, and GIP is described only as a hormone, not as a second drug target. Tirzepatide's label describes it as an agonist at both the GIP and GLP-1 receptors, which is the mechanistic step this lecture could not anticipate.

Second, outcomes. The lecture frames the class purely as glucose-lowering. SUSTAIN-6 had reported a year earlier that semaglutide reduced major cardiovascular events in people with type 2 diabetes from 8.9 percent to 6.6 percent over about two years (PubMed 27633186), and the kidney, heart-failure and sleep-apnoea outcome data all came later.

Third, pancreatitis. The video says there are reports "suggesting increased risk of pancreatitis" attributed to proliferative effects on the pancreas. The current labels list acute pancreatitis under warnings and precautions and instruct discontinuation if suspected, but the large outcome trials have not shown a clear excess, and the proliferation hypothesis has not been confirmed in humans. The caution stands; the mechanism the video offers should be read as a hypothesis from that era.

Where to go next

For the GIP piece the lecture predates, watch the Endocrine Society and CMHC videos in the tirzepatide playlist. For diagrams of the incretin effect, see FormBlends Science. Every current agent, with approval dates and label doses, is on GLP-1s Explained. Compounded semaglutide and tirzepatide, which FormBlends dispenses, are not FDA approved and are not interchangeable with the brand products described in these labels.